Department of Surgery, Rajavithi Hospital, Bangkok, Thailand.
J Cancer Res Clin Oncol. 2010 Oct;136(10):1537-44. doi: 10.1007/s00432-010-0811-1. Epub 2010 Feb 10.
Hilar cholangiocarcinoma (Klatskin tumor) is one of the most difficult cancers to treat. We demonstrate activation of phosphoinositide-3-kinase (PI3K)/Akt signaling, which is a critical pathway for cell survival, in hilar cholangiocarcinoma cells. However, inhibition of PI3K has little effect on hilar cholangiocarcinoma cell survival. In this study, we investigated the mechanism by which hilar cholangiocarcinoma cells resist PI3K inhibitors.
Human hilar cholangiocarcinoma cells KKU-100 were treated with PI3K inhibitors, and cell viability and apoptosis assays were performed. The expression of a MAPK phosphatase (MKP-1) that contributes to cancer cell survival in response to multiple stress stimuli was assayed by quantitative real-time RT-PCR and western blotting. In addition, the effects of the MKP-1 inhibitor were studied in KKU-100 cells treated with PI3K inhibitors.
Incubation of KKU-100 cells with PI3K inhibitors resulted in increased expression of MKP-1. Furthermore, we found that inhibition of MKP-1 using siRNA silencing sensitized KKU-100 cells to PI3K inhibitor-induced apoptosis via increased phosphorylation of p38 MAPK.
These results indicate that concurrent inhibition of PI3K and MKP-1 induces apoptosis in KKU-100 cells. Simultaneous targeting of the PI3K pathway and MKP-1 may be a useful approach to improve therapies directed against hilar cholangiocarcinoma.
肝门部胆管癌(可译为“Klatskin 肿瘤”)是最难治疗的癌症之一。我们证明了磷酸肌醇-3-激酶(PI3K)/Akt 信号通路的激活,这是细胞存活的关键途径,在肝门部胆管癌细胞中。然而,抑制 PI3K 对肝门部胆管癌细胞的存活几乎没有影响。在这项研究中,我们研究了肝门部胆管癌细胞抵抗 PI3K 抑制剂的机制。
用人肝门部胆管癌细胞 KKU-100 处理 PI3K 抑制剂,并进行细胞活力和细胞凋亡测定。通过定量实时 RT-PCR 和 Western blot 测定对 MAPK 磷酸酶(MKP-1)的表达进行了测定,该磷酸酶有助于癌细胞在多种应激刺激下存活。此外,还研究了在 KKU-100 细胞中用 PI3K 抑制剂处理时,MKP-1 抑制剂的作用。
用 PI3K 抑制剂孵育 KKU-100 细胞会导致 MKP-1 的表达增加。此外,我们发现,使用 siRNA 沉默抑制 MKP-1 会通过增加 p38 MAPK 的磷酸化使 KKU-100 细胞对 PI3K 抑制剂诱导的细胞凋亡敏感。
这些结果表明,同时抑制 PI3K 和 MKP-1 可诱导 KKU-100 细胞凋亡。同时针对 PI3K 通路和 MKP-1 可能是改善针对肝门部胆管癌的治疗的一种有用方法。